8AP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Commercial Growth And Launch ExecutionSustained double‑digit revenue growth and rapid prescription pickup for a newly launched specialty product indicate product‑market fit and effective commercial capabilities. Durable launch execution across REMS and specialty channels improves odds of scaling revenues and absorbing fixed commercialization costs over the next 2–6 months.
High Gross MarginsVery high gross margins reflect low incremental cost to supply oral therapies and give the company structural leverage as sales grow. This margin profile supports reinvestment in R&D and commercialization, improving the path to durable operating leverage if revenue scale continues to build.
Conservative Balance Sheet And Ample LiquidityA cash runway exceeding $1B combined with minimal debt provides structural financing flexibility to fund ongoing trials, commercial expansion, and potential delays without immediate dilutive capital raises. Low leverage reduces refinancing risk and supports disciplined execution over the medium term.
Bears Say
Large And Persistent Cash BurnSustained negative operating and free cash flow of several hundred million annually creates structural financing risk if revenue ramp slows. Continued burn will require careful capital management or future financing, which can dilute shareholders or constrain strategic optionality over the coming quarters.
Deep Negative Profitability And Earnings VolatilityVery large negative operating margins and inconsistent profitability weaken return generation and shareholder value creation. Until operating costs are more consistently covered by product revenue, negative ROE and equity erosion risk will persist, complicating long‑term financial stability.
Clinical And Regulatory Uncertainty For Key ProgramsAccelerated approval paths and unexpected PK findings introduce structural execution risk: confirmatory trials and dose investigations can delay commercial expansion, raise development costs, and reduce probability of full label access, affecting long‑term revenue realization for core indications.
Agios Pharma News
8AP FAQ
What was Agios Pharma’s price range in the past 12 months?
Currently, no data Available
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is CHF1.94B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Apr 29, 2026. The company reported -$1.374 earnings per share for the quarter, beating the consensus estimate of -$1.466 by $0.092.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.35.
How many shares outstanding does Agios Pharma have?
Currently, no data Available
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.374 in its last earnings report, beating expectations of -$1.466. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in CH:8AP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF31.78 (― Downside)
CHF31.78 (― Downside)
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.82%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
8AP Stock 12 Month Forecast
Average Price Target
$31.78
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―